607 related articles for article (PubMed ID: 25625843)
21. Epigenetic signatures of familial cancer are characteristic of tumor type and family category.
Joensuu EI; Abdel-Rahman WM; Ollikainen M; Ruosaari S; Knuutila S; Peltomäki P
Cancer Res; 2008 Jun; 68(12):4597-605. PubMed ID: 18559504
[TBL] [Abstract][Full Text] [Related]
22. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
Hong FZ; Wang B; Li HM; Liew CT
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
[TBL] [Abstract][Full Text] [Related]
23. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
[TBL] [Abstract][Full Text] [Related]
24. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
25. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.
Chmelařová M; Křepinská E; Spaček J; Laco J; Nekvindová J; Palička V
Folia Biol (Praha); 2012; 58(6):246-50. PubMed ID: 23438850
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.
Kohler RS; Anugraham M; López MN; Xiao C; Schoetzau A; Hettich T; Schlotterbeck G; Fedier A; Jacob F; Heinzelmann-Schwarz V
Oncotarget; 2016 Aug; 7(32):51674-51686. PubMed ID: 27429195
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors.
Braga Lda C; Silva LM; Piedade JB; Traiman P; da Silva Filho AL
Arch Gynecol Obstet; 2014 May; 289(5):1061-9. PubMed ID: 24190693
[TBL] [Abstract][Full Text] [Related]
28. [Clinicalpathological characteristics of Lynch syndrome related epithelial ovarian cancer].
Ma XG; Wang YM; Xue FX; Zhang HY; Sheng HN; Qi Z; Liu GY
Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):201-4. PubMed ID: 22781072
[TBL] [Abstract][Full Text] [Related]
29. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
31. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
32. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.
Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J
Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226
[TBL] [Abstract][Full Text] [Related]
33. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
34. Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer.
Sung HY; Han J; Ju W; Ahn JH
Oncol Rep; 2016 Jul; 36(1):535-41. PubMed ID: 27220283
[TBL] [Abstract][Full Text] [Related]
35. High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array.
Yoon MS; Suh DS; Choi KU; Sol MY; Shin DH; Park WY; Lee JH; Jeong SM; Kim WG; Shin NR
Oncol Rep; 2010 Oct; 24(4):917-25. PubMed ID: 20811671
[TBL] [Abstract][Full Text] [Related]
36. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
39. Hypermethylation of miR-203 in endometrial carcinomas.
Huang YW; Kuo CT; Chen JH; Goodfellow PJ; Huang TH; Rader JS; Uyar DS
Gynecol Oncol; 2014 May; 133(2):340-5. PubMed ID: 24530564
[TBL] [Abstract][Full Text] [Related]
40. Transcription factor WT1 and promoter CpG hypomethylation coactivate HOXA10 expression in ovarian cancer.
Jiang Y; Chu Y; Tang W; Wan Y; Zhang L; Cheng W
Curr Pharm Des; 2014; 20(11):1647-54. PubMed ID: 23888944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
